Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.41
-0.04 (-1.63%)
Market open: Aug 12, 2026, 1:43 PM EDT
2.49
+0.04 (1.63%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
| Name | Position |
|---|---|
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research & Development and Chief Medical Officer |
| Dr. John Adams Ph.D. | Chief Scientific Officer |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Development Operations |
| Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer |
| Mr. Jeffrey J. Kagy | Chief Human Resources Officer |
| Mr. Mark T. Iwicki | CEO & Director |
| Mr. Timothy J. Pigot | Chief Commercial & Strategy Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | S-8 | d908749ds8.htm |
| 2026-07-29 | 8-K | d78217d8k.htm |
| 2026-07-23 | 8-K | d121491d8k.htm |
| 2026-07-14 | 8-K | d157026d8k.htm |
| 2026-06-29 | 8-K | d68912d8k.htm |
| 2026-05-12 | 8-K | d119997d8k.htm |
| 2026-05-12 | 10-Q | ikt-20260331.htm |
| 2026-04-30 | DEF 14A | ikt-20260430.htm |
| 2026-04-20 | PRE 14A | ikt-20260420.htm |
| 2026-04-07 | 8-K | d108350d8k.htm |